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Possible deleterious effects of
adjunctive omega-3 fatty acids
in post-traumatic stress
disorder patients
Since anger and hostility are frequently pivotal problem
behaviors in post-traumatic stress disorder (PTSD) patients
and depression is a common comorbid feature of PTSD,
we initiated a preliminary open trial of dietary
supplementation with capsules of fish oil rich in
eicosapentaenoic acid (EPA) in a group of PTSD patients
with these problems. Our purpose in the present study was
to examine whether EPA-rich fish oil has any effect on the
symptoms of PTSD patients, especially those related to
depression, anger, and hostility.
We found that we had to severely curtail the study in
response to complaints by our patients, which we feel are
worthy of reporting here, in spite of the open-label nature
and the very small number of participants.
Introduction
PTSD is an incapacitating clinical syndrome characterized
by intrusive recollections, emotional numbing and
withdrawal, cue-related responses, and a chronic state of
combined psychological and physiological hyperarousal
(APA 1994), often expressed as irritability and outbursts of
anger, with difficulties in concentration, perpetual
hypervigilance, and a grossly exaggerated startle response.
Most studies of pharmacotherapy for PTSD agree that
treating the predominant core symptoms and/or the
associated anxiety and depressive symptoms (Davidson
1992; Solomon et al 1992; Davidson and Colket 1997)
affords considerable relief and enables therapeutic and
rehabilitative efforts to be applied with greater hope of
success.
There has been quite a lot of interest concerning the role
of dietary supplements in controlling or affecting various
medical conditions including psychiatric disorders and
sequelae of myocardial infarction. Lately, there has been
special interest in the role of omega-3 fatty acids in mood
disorders (Stoll et al 1999; Freeman 2000; Nemets et al
2002) and chronic ischemic heart disease (CIHD) (Geleijnse
et al 2002). Recent studies of CIHD-prevention have focused
on emotional factors, specifically depression, anger, and
hostility, as being the most likely factors mediating the
beneficial effects of ϖ3-FA in CIHD (Geleijnse et al 2002).
Omega-3 (polyunsaturated) fatty acids (FA) (ϖ3-FA) are
essential long-chain polyunsaturated fatty acids that are
concentrated in the central nervous system, retina, and testes
in humans. Eicosapentaenoic acid (EPA-C20:5n-3) and
docosahexaenoic acid (DHA-22:6n-3) are components of
the ϖ3-FA found in fish oils. It has been shown that dietary
intake of ϖ3-FA has a number of potentially salutary effects,
including a cumulative lowering of the nonesterified FA
concentration in plasma and cell membranes, and
modulation of sodium, potassium, and L-type calcium
channels (Geleijnse et al 2002). They may thus directly
and/or indirectly influence cellular function.
Methods
Subjects
Six consecutive patients fulfilling DSM-IV diagnostic
criteria for PTSD (as assessed by the Structured Clinical
Interview) were recruited from the population under
treatment in the Trauma and Post-Trauma Clinic at the Beer-
Sheva Mental Health Center, Israel, for the pilot phase of
the trial. All patients suffered from moderate to significant
PTSD, with marked problems in controlling anger and
depressive symptoms.
The subject group consisted of three men and three
women, with a mean age of 44.25 (± SD 17.6) years, range
23–66. Types of trauma were vehicle accident = 5 and
combat trauma = 1. Mean time elapsed since trauma was
14.75 (± SD 14.4) years, range 2–31 years. All were
physically healthy, did not abuse substances, and had no
known head trauma.
Two patients were treated with paroxetine 20 mg/day and
two were treated with citalopram 30 mg/day. After receiving
full explanation of the procedures, all subjects signed a
written informed consent approved by the Helsinki Ethics
Committee of Ben-Gurion University.
Study design
The study was a by-product of a large series of studies of
the effect of ϖ3-FA on mental disorders that were being
performed at our center. We elected to perform the pilot
study as an open-label study. After baseline physical
examination and determination of blood chemistry, patients
were assigned to receive ethyl EPA 2 g/day (96% pure
semi-synthetic ethyl-EPA) for about 3 months. The EPANeuropsychiatric Disease and Treatment 2005:1(2) 188
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was supplied by Dr David Horrobin, Laxdale Ltd (Stirling,
UK). Fish taste and smell were minimal. No other
modifications were made to the patients’ diets.
Patients continued their medications and psycho-
therapeutic treatments without change throughout this
period.
The patients were assessed at two time points – at
baseline and at the end point – using the following
instruments: The Symptom Check List (SCL-90-R)
(Derogatis et al 1976) Impact of Event Scale (IES) (Horowitz
et al 1979), State Trait Anger Scale (Speilberger et al 1983),
and Impulsivity Scale (Plutchik and van Praag 1990).
Results
Six patients entered the study. Four patients completed the
trial. Two patients dropped out within the first 3–4 weeks:
one man who “felt no change” and thus refused to continue
and one woman who complained of “feeling greasy all over”.
Psychiatric symptoms, such as hostility, interpersonal
sensitivity, somatization, depression, anxiety, phobia,
obsession, paranoia, and psychoticism were evaluated. At
completion, all the mean symptoms were unchanged as
compared with the baseline symptoms. Assessed in terms
of individual scores, three patients showed mild to moderate
tendencies towards worsening in almost all items, and the
remaining patient showed no change.
The only statistically significant change was a marked
worsening of the avoidance subscale of the IES in all three
of the four patients who demonstrated a general tendency
towards worsening scores on all scales. The remaining
patient was unchanged.
At completion, the specifically targeted anger and
hostility symptoms remained unchanged in both
questionnaires.
Discussion
The results of this abruptly curtailed study suggest that
adjunctive EPA may well be ineffective in relieving either
the anger and hostility or the depressive symptoms in PTSD
patients. This initial PTSD patient sample not only did not
benefit from ϖ3-FA, but rather appears to have experienced
somewhat deleterious effects. The study is very limited in
terms of population number and composition, and in terms
of being open-label, although this is the result of problematic
patient responses to the preparation.
These data, however, do reinforce the results of other
studies of ϖ3-FA in unipolar depression patients (Marangell
et al 2003) and in obsessive-compulsive disorder patients
(Fux et al 2004) where placebo-controlled crossover trials
found that EPA is virtually ineffective.
We have, however, not come across reports of deleterious
effects of ϖ3-FA. Our initial results have alerted us to the
possibility that further study of ϖ3-FA must be performed
with awareness towards the possibility that the preparations
may have potentially deleterious effects in certain patients.
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